Foot drop
Also known as: Foot, Pedes, Feet
Methodology & AI Transparency ⓘ
Foot drop Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Osteoarthritis, Gout & Joint Pain practice, Foot drop (also termed Foot or Pedes) (ICD-10 M21.379) is stratified through topical/targeted anti-inflammatory therapy [Foot drop M21.379], pairing targeted symptom control with longitudinal Weight-Bearing Joint Radiograph [Foot drop M21.379] surveillance.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M21.379 for Foot drop clinical workups.
- 3 Typical cash cost range: Differential triage of Foot drop (M21.379) utilizes topical/targeted anti-inflammatory therapy [Foot drop M21.379].
- 4 Top reported side effects / signs: Follow-up benchmark in Foot drop: maintaining hs-CRP & Erythrocyte in Foot drop (M21.379: Sedimentation Rate) within hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M21.379).
Ask our AI Specialists anything about Foot drop
What Is Foot drop?
Within Osteoarthritis, Gout & Joint Pain practice, Foot drop (also termed Foot or Pedes) (ICD-10 M21.379) is stratified through topical/targeted anti-inflammatory therapy [Foot drop M21.379], pairing targeted symptom control with longitudinal Weight-Bearing Joint Radiograph [Foot drop M21.379] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Foot drop (M21.379) features low-grade synovial metalloproteinase in Foot drop (M21.379: release). therapeutic stabilization in arthritis & joints is verified against Weight-Bearing Joint Radiograph [Foot drop M21.379].
Common Symptoms & Clinical Signs
- • Presentation of Foot drop (M21.379): sudden, intensely painful, in Foot drop (M21.379: red swollen big-toe)
- • Secondary Foot drop clinical sign: localized tendon or in Foot drop (M21.379: bursa tenderness limiting)
- • Symptom flares in Foot drop correlating with hs-CRP & Erythrocyte in Foot drop (M21.379: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M21.379)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Foot drop M21.379] evaluation (M21.379)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Foot drop Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M21.379 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Foot drop (M21.379: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M21.379) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Foot drop M21.379] | Preserved joint-space width (M21.379) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Foot drop (M21.379: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M21.379) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Foot drop
Treatment selection for Foot drop depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Foot drop)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olokizumab, a monoclonal antibody against interleukin 6, in combination with: What a 428-Participant Study Found Treatment with OKZ was associated with significant improvement in signs, symptoms and physical function of autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)) without discernible differences between the two... Annals of the rheumatic diseases • 2022-04-15 • Phase III Randomized Trial | N = 428 | 93/100 | PMID 34344706 ↗ |
| New Insights on EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in: What a 1,008-Participant Study Found CombiRx included 1,008 participants. Neurology • 2021-10-19 • Phase III Randomized Trial | N = 1,008 | 90/100 | PMID 34433679 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III, randomised, gold-standard blind, multi-dose, placebo- and In a difficult-to-treat population with OA, fasinumab 1 mg Q4W achieved clinically meaningful improvements by week 16 versus placebo and naproxen. RMD open • 2026-01-16 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41545313 ↗ |
| Could Berberine Help Stubborn Diabetic Foot Sores Heal Faster? Early Trial Offers Hope In DF patients undergoing TTO, adjunctive local berberine therapy significantly improves the total effective rate and promotes ulcer healing, with benefits associated with reduced inflammation and fibroblast apoptosis and... Pakistan journal of pharmaceutical sciences • 2027-01-01 • Randomized Controlled Trial | N = 48 | 88/100 | PMID 42924998 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term protection of an inactivated enterovirus type 71 vaccine against hand, Under the current EV71 epidemic conditions in China, the two-dose regimen of the inactivated EV71 vaccine provides durable protection exceeding 72% for at least 20 years. Vaccine • 2026-03-19 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41650673 ↗ |
Foot drop Patient Community & “People Like Me” Threads
Filter Foot drop community threads and patient logs by age, biological sex, dosage, and treatment duration.